Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Precision Targeting of Mutant PI3Kα.

Cancer discovery - 8 Feb 2024

Gong Grace Q, Vanhaesebroeck Bart

Abstract excerpt

PIK3CA, which encodes the p110α catalytic subunit of PI 3-kinase alpha (PI3Kα), is one of the most frequently genetically activated kinases in solid tumors. In two back-to-back papers, Varkaris and colleagues report on the development of a novel allosteric PI3Kα-mutant-selective inhibitor and early clinical experience with this compound. See related article by Varkaris et al., p. 227 (6) . See related article by...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Mutation
Share to Phosphatidylinositol 3-Kinases
Share to Phosphoinositide-3 Kinase Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Agents

Share to Class I Phosphatidylinositol 3-Kinases

Share to PIK3CA gene

Share to PI3K/AKT/mTOR signaling in cancer

Share to Protein Kinase Inhibitors

Source

Identifiers

PMID: 38327193
DOI: 10.1158/2159-8290.CD-23-1392

Genes

PIK3CA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Precision Targeting of Mutant PI3Kα.PMID 38327193Read ↗

Structural Insights into the Development of Inhibitors Against Cancer-Specific Mutations of PI3Kα.Semantic proximity Read ↗

Targeting therapeutic liabilities engendered by PIK3R1 mutations for cancer treatment.Semantic proximity Read ↗

Mutated PI 3-kinases: cancer targets on a silver platter.Semantic proximity Read ↗

Cancer-specific mutations in phosphatidylinositol 3-kinase.Semantic proximity Read ↗

The mutational profiles and corresponding therapeutic implications of PI3K mutations in cancer.Semantic proximity Read ↗

Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA-Mutant Cancers.Semantic proximity Read ↗

Targeting PI3K in Cancer: Any Good News?Semantic proximity Read ↗

PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches.Semantic proximity Read ↗

Structure, function and inhibition of the phosphoinositide 3-kinase p110α enzyme.Semantic proximity Read ↗

Phosphatidylinositol 3-kinase (PI3K) inhibitors: a recent update on inhibitor design and clinical trials (2016-2020).Semantic proximity Read ↗

Targeting kinases with precisionSemantic proximity Read ↗

Somatic mutations in PI3Kα: Structural basis for enzyme activation and drug designSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.